134 related articles for article (PubMed ID: 2829717)
1. Antagonism of wild-type and resistant Escherichia coli and its DNA gyrase by the tricyclic 4-quinolone analogs ofloxacin and S-25930 stereoisomers.
Wolfson JS; Hooper DC; Ng EY; Souza KS; McHugh GL; Swartz MN
Antimicrob Agents Chemother; 1987 Nov; 31(11):1861-3. PubMed ID: 2829717
[TBL] [Abstract][Full Text] [Related]
2. Mechanism of differential activities of ofloxacin enantiomers.
Morrissey I; Hoshino K; Sato K; Yoshida A; Hayakawa I; Bures MG; Shen LL
Antimicrob Agents Chemother; 1996 Aug; 40(8):1775-84. PubMed ID: 8843280
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of DNA gyrase by optically active ofloxacin.
Imamura M; Shibamura S; Hayakawa I; Osada Y
Antimicrob Agents Chemother; 1987 Feb; 31(2):325-7. PubMed ID: 3032098
[TBL] [Abstract][Full Text] [Related]
4. Ciprofloxacin and the fluoroquinolones. New concepts on the mechanism of action and resistance.
Fisher LM; Lawrence JM; Josty IC; Hopewell R; Margerrison EE; Cullen ME
Am J Med; 1989 Nov; 87(5A):2S-8S. PubMed ID: 2574005
[TBL] [Abstract][Full Text] [Related]
5. Antibacterial activity of ofloxacin and its mode of action.
Sato K; Inoue Y; Fujii T; Aoyama H; Mitsuhashi S
Infection; 1986; 14 Suppl 4():S226-30. PubMed ID: 3028966
[TBL] [Abstract][Full Text] [Related]
6. Chiral DNA gyrase inhibitors. 2. Asymmetric synthesis and biological activity of the enantiomers of 9-fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H- pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid (ofloxacin).
Mitscher LA; Sharma PN; Chu DT; Shen LL; Pernet AG
J Med Chem; 1987 Dec; 30(12):2283-6. PubMed ID: 2824776
[TBL] [Abstract][Full Text] [Related]
7. In vivo selection during ofloxacin therapy of Escherichia coli with combined topoisomerase mutations that confer high resistance to ofloxacin but susceptibility to nalidixic acid.
Cattoir V; Lesprit P; Lascols C; Denamur E; Legrand P; Soussy CJ; Cambau E
J Antimicrob Chemother; 2006 Nov; 58(5):1054-7. PubMed ID: 16984897
[TBL] [Abstract][Full Text] [Related]
8. Quinolone-resistant mutants of escherichia coli DNA topoisomerase IV parC gene.
Kumagai Y; Kato JI; Hoshino K; Akasaka T; Sato K; Ikeda H
Antimicrob Agents Chemother; 1996 Mar; 40(3):710-14. PubMed ID: 8851598
[TBL] [Abstract][Full Text] [Related]
9. In vitro selection of fluoroquinolone-resistant Neisseria gonorrhoeae harboring alterations in DNA gyrase and topoisomerase IV.
Yasuda M; Fukuda H; Yokoi S; Ishihara S; Kawada Y; Deguchi T
J Urol; 2000 Sep; 164(3 Pt 1):847-51. PubMed ID: 10953166
[TBL] [Abstract][Full Text] [Related]
10. Role of the extended alpha4 domain of Staphylococcus aureus gyrase A protein in determining low sensitivity to quinolones.
Strahilevitz J; Robicsek A; Hooper DC
Antimicrob Agents Chemother; 2006 Feb; 50(2):600-6. PubMed ID: 16436716
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms of action of and resistance to ciprofloxacin.
Hooper DC; Wolfson JS; Ng EY; Swartz MN
Am J Med; 1987 Apr; 82(4A):12-20. PubMed ID: 3034057
[TBL] [Abstract][Full Text] [Related]
12. Gatifloxacin activity against quinolone-resistant gyrase: allele-specific enhancement of bacteriostatic and bactericidal activities by the C-8-methoxy group.
Lu T; Zhao X; Drlica K
Antimicrob Agents Chemother; 1999 Dec; 43(12):2969-74. PubMed ID: 10582891
[TBL] [Abstract][Full Text] [Related]
13. Activities of trovafloxacin compared with those of other fluoroquinolones against purified topoisomerases and gyrA and grlA mutants of Staphylococcus aureus.
Gootz TD; Zaniewski RP; Haskell SL; Kaczmarek FS; Maurice AE
Antimicrob Agents Chemother; 1999 Aug; 43(8):1845-55. PubMed ID: 10428901
[TBL] [Abstract][Full Text] [Related]
14. In vitro and in vivo antibacterial activity of T-3912, a novel non-fluorinated topical quinolone.
Yamakawa T; Mitsuyama J; Hayashi K
J Antimicrob Chemother; 2002 Mar; 49(3):455-65. PubMed ID: 11864945
[TBL] [Abstract][Full Text] [Related]
15. Differential behaviors of Staphylococcus aureus and Escherichia coli type II DNA topoisomerases.
Blanche F; Cameron B; Bernard FX; Maton L; Manse B; Ferrero L; Ratet N; Lecoq C; Goniot A; Bisch D; Crouzet J
Antimicrob Agents Chemother; 1996 Dec; 40(12):2714-20. PubMed ID: 9124828
[TBL] [Abstract][Full Text] [Related]
16. Dual Escherichia coli DNA Gyrase A and B Inhibitors with Antibacterial Activity.
Fois B; Skok Ž; Tomašič T; Ilaš J; Zidar N; Zega A; Peterlin Mašič L; Szili P; Draskovits G; Nyerges Á; Pál C; Kikelj D
ChemMedChem; 2020 Feb; 15(3):265-269. PubMed ID: 31721445
[TBL] [Abstract][Full Text] [Related]
17. Impact of mutations in DNA gyrase genes on quinolone resistance in Campylobacter jejuni.
Changkwanyeun R; Yamaguchi T; Kongsoi S; Changkaew K; Yokoyama K; Kim H; Suthienkul O; Usui M; Tamura Y; Nakajima C; Suzuki Y
Drug Test Anal; 2016 Oct; 8(10):1071-1076. PubMed ID: 26857529
[TBL] [Abstract][Full Text] [Related]
18. International experiences with ofloxacin, a new quinolone.
Mitsuhashi S
Infection; 1986; 14 Suppl 4():S223-5. PubMed ID: 3028965
[TBL] [Abstract][Full Text] [Related]
19. Mechanism of action of quinolones against Escherichia coli DNA gyrase.
Yoshida H; Nakamura M; Bogaki M; Ito H; Kojima T; Hattori H; Nakamura S
Antimicrob Agents Chemother; 1993 Apr; 37(4):839-45. PubMed ID: 8388200
[TBL] [Abstract][Full Text] [Related]
20. Cleavable-complex formation by wild-type and quinolone-resistant Streptococcus pneumoniae type II topoisomerases mediated by gemifloxacin and other fluoroquinolones.
Yague G; Morris JE; Pan XS; Gould KA; Fisher LM
Antimicrob Agents Chemother; 2002 Feb; 46(2):413-9. PubMed ID: 11796351
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
